Traditional chemotherapy for cancer patients is as dreaded as the disease itself. But Delcath’s “Chemosaturation System,” which is doing well so far in tests, promises to deliver treatments far more precisely, thus limiting side effects.
Continue reading Inside Wall Street: The Allure of Delcath’s Highly Targeted Chemotherapy
Inside Wall Street: The Allure of Delcath’s Highly Targeted Chemotherapy originally appeared on DailyFinance on Mon, 11 Oct 2010 07:00:00.
Filed Under: Company News, Columns, Investing, Health Care, Stock Picks